What to look for in the upcoming gene therapy pipeline
As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.
Read MoreLeveraging biosimilars to drive savings and support patient access
By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.
Read MoreBoosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read MoreExpress Scripts Introduces New Option to Give Clients Maximum Simplicity in Drug Pricing
Express Scripts ClearNetwork offers employers and health plans a new option for simple, “cost-plus” pharmacy pricing for brand, generic, and specialty medications.
Read MoreCoupling Cancer Diagnosis and Treatment with Behavioral Health Care Can Improve Health Outcomes for Oncology Patients
Being diagnosed and living with cancer can cause significant psychological stress.
Read MoreHow to stay ahead of a rapidly evolving utilization management landscape
Regulatory pressures and technological advancements are changing utilization management as we know it—here’s what plan sponsors should know.
Read MoreHow Accredo’s physician engagement team simplifies the experience for prescribers
The team focuses on highly complex medications, including treatments for cancer, neurological diseases, pulmonary conditions, and bleeding disorders.
Read MoreWhy a home infusion strategy is more important than ever
Growing demand and new regulations have put the onus on plan sponsors to prioritize the need for a comprehensive home infusion strategy.
Read More